Technical Description
The present invention provides the synthesis of novel quinolinyl piperazine derivatives for the treatment of Alzheimer’s disease by dual inhibition of β-secretase (BACE1) and acetylcholineesterase (AChE).
Problems Addressed
- Aβ Accumulation in Brain
- Single Target Therapy
- Current Treatment Limitations
- Decreased Cholinergic Activity
Tech Features
- Affordable
- Novel Component
- Neurodegenerative Disease Treatment
- AChE, BuChE & BACE1 Inhibitors
- Final Edge Identification
- Enhanced BBB Permeability
Target Audience
- Healthcare & Medical Sector
- Pharmaceutical Industry
- Biotechnology Firms
- Research and Development
Tech ID: P21-1237 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
